Semaglutide and Tirzepatide Lead Weight Loss, Semaglutide Reduces Mortality in Obesity Meta-analysis
Background
Pharmacologic treatments for overweight and obesity are crucial given their strong links to type 2 diabetes, coronary heart disease, and stroke, all of which increase mortality risk. While lifestyle interventions are foundational, many individuals require additional support to achieve and maintain significant weight loss. Current pharmacotherapies vary widely in efficacy and safety, necessitating a comprehensive comparison to guide clinical decisions. This review aimed to synthesize evidence on various agents, including GLP-1 receptor agonists and multi-agonists, to identify the most beneficial options for long-term weight management and associated health outcomes.
Study Design
Researchers conducted a living systematic review and network meta-analysis, including 69 randomized controlled trials with a total of 112,511 participants. The studies compared pharmacologic treatments for weight management in adults with overweight or obesity (BMI ≥25 kg/m2). Interventions included dulaglutide, exenatide, liraglutide, lixisenatide, naltrexone-bupropion, orforglipron, phentermine, phentermine-topiramate, retatrutide, semaglutide, semaglutide-cagrilintide, and tirzepatide, alone or combined with lifestyle intervention (LI). Data sources were MEDLINE and Cochrane Central Register of Controlled Trials until October 2025, focusing on outcomes such as mortality, weight loss, and quality of life.
Results
The meta-analyses revealed that nearly all studied pharmacologic interventions were more effective than placebo and/or lifestyle intervention in reducing weight. However, these treatments also led to more discontinuations due to adverse events. Notably, semaglutide probably reduced overall mortality and major adverse cardiovascular events (MACE). Both semaglutide and tirzepatide demonstrated the most significant weight loss compared with placebo and/or LI in both pairwise and network meta-analyses. The review included 69 studies, with 37 assessed as having a low risk of bias. Despite these findings, evidence for critical outcomes such as mortality, MACE, and serious adverse events was limited across many treatments. This highlights the need for more robust data in these areas.
Semaglutide and tirzepatide consistently led to the greatest weight loss, with semaglutide uniquely showing a probable reduction in mortality and
MACE.
Key Findings
- Nearly all pharmacologic interventions were more effective than placebo/lifestyle intervention for weight reduction.
- Semaglutide and tirzepatide led to the greatest weight loss among all studied treatments.
- Semaglutide probably reduced overall mortality and major adverse cardiovascular events (
MACE). - More discontinuations due to adverse events were observed across pharmacologic treatments compared to placebo.
Why It Matters
This comprehensive meta-analysis provides critical guidance for individuals and clinicians navigating pharmacologic options for weight management. Semaglutide and tirzepatide are strongly affirmed as leading interventions, not just for weight loss but also for potentially improving cardiovascular outcomes and reducing mortality with semaglutide. This reinforces their position as first-line choices for many patients. For those considering these peptides, the findings underscore their superior efficacy compared to other agents, while also highlighting the importance of monitoring for adverse events. The review's 'living' nature means it will continue to incorporate new evidence, ensuring the most up-to-date recommendations for optimizing treatment protocols and patient outcomes.
meta-analysis
obesity
overweight
weight-loss
semaglutide
tirzepatide